Search research articles
Contact Us
Filters
Showing results (21-30 of 58) with videos related to
Page
of 6
Sort By:
The Journal of Thoracic and Cardiovascular Surgery
|
April 6, 2015
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids
Hongyi Lei, Sophie C Hofferberth, Rong Liu, et al.
Brachytherapy
|
August 22, 2017
MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer
Sophia C Kamran, Matthias M Manuel, Paul Catalano, et al.
Cancer
|
October 15, 2013
Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model
Monica S Krishnan, Zachary Epstein-Peterson, Yu-Hui Chen, et al.
Oncology
|
October 18, 2017
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
Jordan D Berlin, Yang Feng, Paul Catalano, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 29, 2021
Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials
Jonathan E Leeman, Yu-Hui Chen, Paul Catalano, et al.
Investigational New Drugs
|
October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Gynecologic Oncology
|
May 24, 2016
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy
Larissa J Lee, Brooke Howitt, Paul Catalano, et al.
Head & Neck
|
April 16, 2016
Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer
Florence K Keane, Yu-Hui Chen, Roy B Tishler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
The Oncologist
|
February 20, 2026
ECOG 6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer
Chengwei Peng, Paul Catalano, John Zalcberg, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 58) with videos related to
Sort By:
Page
of 6
The Journal of Thoracic and Cardiovascular Surgery
|
April 6, 2015
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids
Hongyi Lei, Sophie C Hofferberth, Rong Liu, et al.
Brachytherapy
|
August 22, 2017
MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer
Sophia C Kamran, Matthias M Manuel, Paul Catalano, et al.
Cancer
|
October 15, 2013
Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model
Monica S Krishnan, Zachary Epstein-Peterson, Yu-Hui Chen, et al.
Oncology
|
October 18, 2017
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
Jordan D Berlin, Yang Feng, Paul Catalano, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 29, 2021
Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials
Jonathan E Leeman, Yu-Hui Chen, Paul Catalano, et al.
Investigational New Drugs
|
October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Gynecologic Oncology
|
May 24, 2016
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy
Larissa J Lee, Brooke Howitt, Paul Catalano, et al.
Head & Neck
|
April 16, 2016
Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer
Florence K Keane, Yu-Hui Chen, Roy B Tishler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
The Oncologist
|
February 20, 2026
ECOG 6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer
Chengwei Peng, Paul Catalano, John Zalcberg, et al.
Page
of 6